Meta Shares Down 21% from Peak Despite $14 Billion Health AI Investment
META•Meta’s Chief AI Officer Alexandr Wang says future AI models will center on health features in consumer platforms after the company’s $14 billion investment in Scale AI. Shares are down 21% from their all-time high but have historically rebounded by up to 75% after past declines of similar magnitude.
1. Health-Centric AI Strategy
Meta's Chief AI Officer Alexandr Wang has indicated that consumer health will be a primary focus for future AI models, targeting features such as diagnoses, fitness guidance and mental health support across Instagram, Facebook and WhatsApp. This strategic pivot follows the April release of Muse Spark and builds on Meta’s $14 billion investment in Scale AI, with internal tests showing strong performance in health-related tasks while mitigating biological-risk concerns.
2. Stock Decline and Past Rebounds
Meta Platforms shares have fallen 21% from their all-time high, reflecting investor concerns over heavy AI spending and ROI timelines. Historical analysis shows that after previous steep declines—32% in 2018, 30% in 2020 and 75% in 2021–2022—Meta stock rebounded by as much as 75%, suggesting potential upside for long-term investors.
